Abstract Background Intragastric balloon (IGB) is a temporary and minimally invasive option for overweight and obesity treatment, acting as a space occupying device which leads to weight loss reducing gastric capacity and inducing satiety. Objective Review our intragastric balloon usage as a primary therapy for overweight and obese patients in Guatemala. Results The total number of IGB procedures was 70. The mean patient age was 33.8 years, with 84.3% being female. The youngest patient was 16 years old and the oldest was 56 years old. The mean pre procedure BMI was 31.8 kg/m2. The minimum pre procedure BMI was 25.5 kg/m2 and the maximum was 66 kg/m2. The most frequently used balloon was the adjustable fluid-filled balloon Spatz3 totalling 46 implants (66%). This was followed by nonadjustable fluid-filled balloons Silimed (17%) and Orbera (8.5%). The Helioscopie air-filled balloon was used in 8.5% of cases. The overall mean percentage of total body weight loss (TBWL) at 12 months was 14.55% + 8.47%. The minimum percent of TBWL was 3% and the maximum was 34.2%. The failure rate (defined as TBWL <10%) was 6.87% + 2.34%. No serious adverse events were reported. The early removal rate due to intolerance was 4.2% (3/70). Conclusions Intragastric balloon as a primary endoscopic bariatric treatment for overweight and obese patients at a one-year period is a safe and effective procedure as compared to the data in the literature.